Medicine and Dentistry
Atrial Fibrillation
100%
Catheter Ablation
69%
Atrial Flutter
55%
Thromboembolism
55%
Paroxysmal Atrial Fibrillation
55%
Catheter Ablation
44%
Cohort Analysis
27%
Exercise
27%
Persistent Atrial Fibrillation
27%
Randomized Controlled Trial
27%
Coronary Artery Bypass Surgery
27%
Systematic Review
27%
Attitude
27%
Vein Graft
27%
Pulmonary Vein Isolation
27%
Quality of Life
27%
Hazard Ratio
19%
Graft Failure
18%
Antiarrhythmic Agent
16%
Invasive Procedure
16%
Observational Study
15%
Prevalence
13%
All Cause Mortality
13%
Recurrent Disease
12%
Ablation Therapy
11%
Mortality Rate
11%
Sinus Rhythm
11%
Cardioversion
10%
Rehabilitation Engineering
9%
Myocardial Infarction
9%
Angina pectoris
9%
Cosmetics
9%
Coronary Angiography
9%
Wound Complication
9%
Leg
9%
Meta-Analysis
7%
Radiofrequency Ablation
5%
Holter Monitoring
5%
Epileptic Absence
5%
Pulmonary Vein
5%
Electrocardiogram
5%
Keyphrases
Laropiprant
27%
Extended-release Niacin
27%
Patency Rate
27%
Paroxysmal Atrial Fibrillation
27%
Thoracoscopic Ablation
27%
Pulmonary Vein Ablation
27%
Patient Education
27%
Exercise Capacity
27%
Education Training
27%
Physical Training
27%
Physical Exercise
27%
Anacetrapib
27%
Persistent Atrial Fibrillation
27%
Quality of Life
27%
Atrial Fibrillation
22%
Vein Graft Failure
18%
Intervention Group
16%
Niacin
13%
Major Vascular Injury
13%
Long-standing Atrial Fibrillation
13%
Spontaneous Echo Contrast
11%
Rehabilitation Program
11%
Percutaneous Catheter
11%
Atrial Flutter Ablation
10%
Graft Harvesting
9%
Group 13
9%
Leg Wound Complication
9%
In-hospital Death
9%
Left Atrial Thrombus
5%
Ablation Study
5%
Generalized Anxiety Disorder-7 (GAD-7)
5%
Patient Health Questionnaire
5%
Between-group
5%
Difference in Means
5%
Pulmonary Vein
5%
Repeated Measures Analysis of Variance
5%
Quality of Life Questionnaire
5%
Patient Health Questionnaire-9 (PHQ-9)
5%
Generalized Anxiety Disorder
5%
Physical Capacity
5%
EQ-5D
5%
Submaximal Exercise
5%
Exercise Test
5%
Training Intervention
5%
Beneficial Effects
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
55%
Heart Atrium Flutter
55%
Atrial Fibrillation
55%
Nicotinic Acid
27%
Laropiprant
27%
Disease Exacerbation
27%
Thromboembolism
27%
Anacetrapib
27%
Heart Arrhythmia
12%
Heart Failure
12%
Mortality Rate
11%
Observational Study
6%
All Cause Mortality
6%
